Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to modulate disease
Gainers
Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm
LA JOLLA, CA, April 25, 2023 (GLOBE